State of the art - Treatment of peripheral occlusive arterial disease (POAD) with drugs vs. vascular reconstruction or amputation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 7, 1997, Pages 266-274

  Haustein, K O ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Buflomedil; Epidemiology; Naftidrofuryl; Pentoxifyllin; Peripheral occlusive arterial disease; Surgical therapy

Indexed keywords

BUFLOMEDIL; FIBRINOGEN; NAFTIDROFURYL; PENTOXIFYLLINE; PROSTAGLANDIN E1; VASOACTIVE AGENT;

AMPUTATION; BLOOD VESSEL SHUNT; ERYTHROCYTE DEFORMABILITY; FIBRINOGEN BLOOD LEVEL; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMA VISCOSITY; REVIEW; STENT; THROMBOCYTE AGGREGATION; VASCULAR SURGERY;

AMPUTATION; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR AGENTS; HUMANS; LIFE STYLE; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 0030747357     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Accetto B 1982 Beneficial hemorrheologic therapy of chronic peripheral arterial disorders with pentoxifyllin: results of double-blind study versus vasodilataor nylidrin. Am Heart J 103: 864-869
2. Adhoute G, Andreassian B, Boccalon H et al 1990 Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 16 (Suppl 3): S75-S80
3. Adhoute G, Bacourt F, Barrai M et al 1986 Naftidrofuryl in chronic arterial disease. Results of a six-month controlled multicenter study using Naftidrofuryl tablets 200 mg. Angiology 37: 160-167
4. Anderson TJ et al 1993 Cholesterol-lowering therapy improves endothelial function in patients with coronary atherosclerosis. Circulation 88: 368
5. Barradell LB, Brogden RN 1996 Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8: 299-322
6. Becker HM, Elert O, Häring R et al 1979 Wirksamkeitsnachweis von Dusodril-Pi bei arterieller Verschlußkrankheit. Med Welt 30: 1602-1606
7. Begg TB, Richards RL 1962 The prognosis of intermittent claudication. Scot Med J 1: 341-345
8. Bevan EG, Waller PC, Ramsay LE 1992 Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging 2: 125-136
9. Bisler H 1983 Klinische Erfolge der Buflomediltherapie bei arterieller Verschlußkrankheit. Therapiewoche 33: 2204-2210
10. Blankenhorn DH, Nessin SA, Johnson RL 1987 Beneficial effects of combined colestipol-niacin therapy on atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 257: 3233-3240
11. Bloor K 1961 Natural history of arteriosclerosis of the lower extremities. Ann R Coll Surg 28: 36-41
12. Bollinger A, Frei C 1977 Double-blind study of pentoxifylline against placebo with intermittent claudication. Pharmatherapeutica 1: 557-562
13. Borhani NO, Mercuri M, Borhani PA et al 1996 Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). J Am Med Assoc 276: 785-790
14. Brown BG, Albers JJ, Fisher LD et al 1990 Regression of coronary artery disease as a result of intensive lipid-lowering therapy in man with high levels of lipoprotein B. N Engl J Med 323: 1289-1291
15. Cameron HA, Waller PC, Ramsay LE 1988 Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol 26: 569-576
16. Clissold SP, Lynch S, Sorkin EM 1987 Buflomedil: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs 33: 430-460
17. Clyne CAC, Galland RB, Fox MJ et al 1980 A controlled trial of naftidrofuryl (Praxiene) in the treatment of intermittent claudication. Br J Surg 67: 347-348
18. Criqui MH, Fronek A, Klauber MR et al 1985 The sensitivity, specifity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in an defined population. Circulation 71: 516-522
19. Cummings DM, Ballas SK, Ellison MJ 1992 Lack of effect of pentoxifylline on red blood cell deformability. J Clin Pharmacol 32: 1050-1053
20. DeCree J, Leempoels J, Geukens H et al 1984 Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication. Lancet 2: 775-779
21. Dormandy JA, Hoare E, Colley J et al 1973 Clinic, haemodynamic, rheological and biochemical findings in 126 patients with intermittent claudication. Br Med J 4: 576-581
22. Dubourg A, Scamuffa RF 1981 An experimental overview of a new vasoactive drug: buflomedil HCl. Angiology 32: 663-675
23. Eickhoff JH 1993 Changes in the number of lower limb amputations during a period of increasing vascular surgical activity. Results of a nation-wide study, Denmark, 1977-1990. Eur J Surg Acta Chir 159: 469-473
24. Ely H 1989 White blood cells as mediator of hyperviscosity-induced tissue damage in neutrophilic vascular reactions: Therapy with pentoxifylline. J Am Acad Dermatol 20: 677-680
25. Ernst CB, Rutkow IM, Cleveland RJ et al 1987 Vascular surgery in the United States: report of the Joint Society for Vascular Surgery -International Society for Cardiovascular Surgery Committee on Vascular Surgical Manpower. J Vasc Surg 6: 611-621
26. Ernst E, Matrai A, Kollar L 1987 Placebo-controlled double-blind study of haemodilution in peripheral arterial disease. Lancet 1: 1449-1451
27. Frampton JE, Brogden RN 1995 Pentoxifylline (Oxpentifylline). A review of its therpeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 7: 480-503
28. Greenhalagh RM 1971 Serum lipids and lipoproteins in peripheral vascular disease. Lancet 2: 947-950
29. Halpern JL 1996 Coronary artery disease and peripheral vascular disease. Cardiol Rev 4: 25-33
30. Heidrich H, Barckow D, Grand M, Fontaine L 1972 Klinische und tierexperimentelle Untersuchungen zur hämodynamischen Wirkungsweise von Naftidrofuryl. Arzneimittel-Forsch 22: 1001-1004
31. Heidrich H, Ranft J 1988 Kapillarmikroskopische Untersuchungen zum Naftidrofuryl bei peripherer arterieller Verschlußkrankheit. VASA Suppl 24: 17-20
32. Imparto AM, Kim G, Davidson T et al 1975 Intermittent claudication: its natural course. Surgery 78: 795-799
33. Joffre F, Meites G, Rousseau H et al 1994 Effect de perfusions de buflomédil sur l'oxygénation tissulaire périphérique au décours immédiat d'angioplasties endoluminales réalisées chez des patients souffrant d'une artériopathie évoluée des membres inférieurs. Ann Radiol 37: 239-244
34. Jung F, Kiesewetter H, Mrowietz C et al 1987 Hemorrheological, micro-and macro-circulatory effects of naftidrofuryl in an acute study: a randomized, placebo-controlled, double-blind individual comparison. Int J Clin Pharmacol Ther 25: 507-514
35. Kallero KS 1981 Mortality and morbidity in patients with intermittent claudication as defined by venous occlusion plethysmography. A ten-year follow-up. J Chron Dis 34: 455-462
36. Kannel WB, McGee DL 1979 Diabetes and cardiovascular disease: The Framingham Study. J Am Med Assoc 241: 2035-2038
37. Kannel WB, McGee DL 1985 Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 33: 13-18
38. Kannel WB, Shurtleff D 1973 Cigarettes and the development of intermittent claudication. Geriatrics 28: 61-68
39. Kannel WB, Skinner JJ, Schwartz MJ et al 1970 Intermittent claudication. Incidence in The Framingham Study. Circulation 41: 875-883
40. Kiesewetter H, Blume J, Jung F et al 1987 Gehtraining und medikamentöse Therapie bei der peripheren arteriellen Verschlußkrankheit. Randomisierte, prospektive, placebo-kontrollierte Doppelblindstudie. Dtsch Med Wochenschr 112: 873-878
41. Kiesewetter H, Jung F 1990 Wirkungen von Naftidrofuryl auf Makro-, Mikrozirkulation, Gewebssauerstoffversorgung und Fließfähigkeit des Blutes. VASA 30 (Suppl): 79-83
42. Klimm HD, Huppertz E 1996 Mortalitätsbetrachtungen bei pA VK-Patienten einer angiologischen Spezialambulanz mit und ohne vasoaktive Medikation - eine retrospektive Untersuchung. VASA 45 (Suppl): 1-5
43. Koch LG, Alsip NL, Feige BD et al 1994 In vivo effect of naftidrofuryl on 5-hydroxy-tryptamine-mediated constriction in rat peripheral microcirculation. Eur J Pharmacol 254: 249-255
44. Költinger P, Langsteger W, Reisecker F et al 1990 Die Wirkung von Naftidrofuryl auf die Viskoelastizität, die Thrombozytenaggregation und die Erythrozytenfluidität des Blutes. VASA 21: 411-414
45. Kriessmann A, Neiss A 1988 Clinical effectiveness of naftidrofuryl in intermittent claudication. VASA 24 (Suppl): 27-32
46. Kriessmann A, Neuss A, Lutilsky L et al 1979 Medikamentöse Behandlung der Claudicatio intermittens im Stadium IIb der arteriellen Verschlußkrankheit. Med Welt 30: 888-891
47. Kriessmann A, Rädler M 1973 Änderung der Unterschenkeldurchblutung während oraler Behandlung mit Naftidrofuryl. Münch Med Wochenschr 155: 508-510
48. Kritz H, Sinzinger H 1996 Pharmacological prevention of myointimal hyperplasia (restenosis) following angioplasty. Gefäßchirurgie 1: 3-14
49. Kronen G, Ferder M, Hunzicker K et al 1993 The use of pentoxifylline in microvascular surgery. J Reconstr Microsurg 10: 17-20
50. Kuhn FE, Mohler ER, Rackley CE 1992 Cholesterol and lipoproteins: beyond atherogenesis. Clin Cardiol 15: 883-890
51. Lääperi T, Pohjolainen T, Alaranta H et al 1993 Lower limb amputations. Ann Chir Gynaecol 82: 183-187
52. Le Dèvéhat C, Vimeux M, Bondoux G et al 1991 Effects of buflomedil on microvascular disorders in diabetic patients. Blood Vessels 28: 38-43
53. LeFevre FA, Corbacioglu C, Humphries AW et al 1959 Management of arteriosclerosis obliterans of the extremities. J Am Med Assoc 170: 656-658
54. Lehert P, Riphagen FE, Gamand S 1990 The effect of naftidrofuryl on intermittent claudication: a metaanalysis. J Cardiovasc Pharmacol 16 (Suppl 3): 81-86
55. Lehert P, Comte S, Gamand S et al 1994 Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 23 (Suppl 3):S48-S52
56. Lichtlen PR, Hugenholtz PG, Rafflenbeul W et al 1990 Retardation of coronary artery disease in man by the calcium channel blocker nifedipine. Results of INTACT (International Nifedipine Trial on Antiatherosclerotic Therapy). Lancet 335: 1109-1113
57. Lindegarde F, Jelnes R, Bjorkman H et al 1989 Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 80: 1549-1556
58. Lowe GDO, Fowkes FGR, Dawes J et al 1993 Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edingburgh artery study. Circulation 87: 1915-1920
59. Maass U, Amberger HG, Böhme H et al Wirksamkeitsnachweis von Dusodril-Pi bei arterieller Verschlußkrankheit. Dtsch Med Wochenschr 109: 745-750
60. Maloteaux JM, Haiech D, Campeneere DE et al 1986 Biochemical and physiological evidences for antiserotonergic properties of naftidrofuryl. Drug Res 36: 1194-1198
61. McDaniel MD, Cronenwett JL 1989 Basic data related to the natural history of intermittent claudication. Ann Vasc Surg 3: 273-277
62. Nagashima H, Inoue H, Takechi H 1993 Incidence and prognosis of dysvascular amputations on Okayama Prefecture (Japan). Prosthet Orthot Int 17: 9-13
63. National Center for Health Statistics 1984 Vital Statistics of USA: Vol. II, Sect 6, Life tables. DHHS publication No. (PHS). Public Health Service, Washington, DC: US Governm Printing Office, 84-1104
64. Ouriel K, Flore WM, Geary JE 1986 Limb-threatening ischemia in the medically compromised patient: amputation or revascularization? Surgery 104: 667-672
65. Pell JP, Fowkes FGR 1992 Risk factors for critical limb ischaemia. Crit Ischaemia 2: 19-25
66. Pell JP, Fowkes FGR, Ruckley CV et al 1994 Declining incidence of amputation for arterial disease in Scotland. Eur J Vasc Surg 8: 602-606
67. Pentti J, Salenius JP, Kuukasjarvi P et al 1995 Outcome of surgical treatment in acute upper limb ischemia. Ann Chir Gynaecol 84: 25-28
68. Perego MA, Sergio G, Espureo M et al 1982 Hemodynamic and hemorrheological effects of buflomedil in patients with peripheral occlusive arterial disease. Curr Med Res Opin 8: 178-187
69. Perler BA 1995 Cost-efficacy issues in the treatment of peripheral vascular disease: Primary amputation or revascularization for limbthreatening ischemia. J Vasc Intervent Radiol 6. 111S-115S
70. Poggesi L, Scarti L, Boddi M et al 1985 Pentoxifyllin treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis. Angiology 36: 628-637
71. Pohjolainen T, Ataranta H 1988 Lower limb amputations in Southern Finland 1984-1985. Prosthet Orthot Int 12: 9-18
72. Porter JM, Cutler BC, Lee BY et al 1982 Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104: 66-72
73. Radack K, Wyderski RJ 1990 Conservative management of intermittent claudication of the lower limbs. Ann Intern Med 113: 135-146
74. Radtke H, Kiesewetter H, Roggenkamp HG, Jung F 1983 Zur rheologischen Wirksamkeit von Naftidrofuryl und Pentoxifyllin. Med Welt 34: 833-836
75. Raviola CA, Nichter LS, Baker JS et al 1988 Cost of threatening advanced leg ischemia: bypass graft vs primary amputation. Arch Surg 123: 495-496
76. Rieger H 1995 Risikoprädiktion und risikoadaptierte Prävention bei peripheren arteriellen Verschlußkrankheiten. Internist 36: 902-908
77. Rudofsky G, Hirche H 1989 Verlauf präklinischer Arteriosklerose bei Risikopatienten. Eine Untersuchung über die Möglichkeiten medikamentöser Prävention bei arteriellen Verschlußkrankheiten. Natur Gesamtheitsmed 3: 64-68
78. Rudofsky G, van Laak HH 1994 Treatment costs of peripheral arterial occlusive disease in Germany: a comparison of costs and efficacy. J Cardiovasc Pharmacol 23 (Suppl 3): S22-S25
79. Ryckewaert JJ, Maurel A, Marguerie G 1990 In vitro studies of the effect of buflomedil on platelet responsiveness. Hemostasis 20: 181-191
80. Sayers RD, Thompson MM, Varty K et al 1993 Effects of the development of modern vascular services on amputations rates in Leicester, U.K.: A preliminary report. Ann Vase Surg 7: 102-105
81. Schadt DC 1961 Chronic atherosclerotic occlusion of the femoral artery. J Am Med Assoc 175: 937-940
82. Schönharting M, Musikic P, Müller R 1988 The haemorrheological and antithrombotic potential of pentoxifylline (Trental): a review. Pharmatherapeutica 5: 159-169
83. Schoop W 1991 Spontanverlauf der peripheren, stenosierenden Arteriosklerose und Einfluß von Katheterinterventionen. Z Kardiol 80 (Suppl 9): 21-29
84. Shields DA, Scurr JH 1994 Treatment of the critically ischaemic lower limb. Postgr Med J 70: 5-9
85. Soria J, Lancrenon S, Chassoux G 1989 Fibrinoène et pentoxifylline. Resultats d'une étude cooperative francaise exploratoire dans l'artérite au stade II. J Malad Vasculaires (Paris) 14: 29-34
86. Sowers JR 1992 Insuline resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis. Clin Pharmacol 32: 529-535
87. Taylor GW, Calo AR 1962 Atherosclerosis of arteries of lower limbs. Br Med J 1: 507-510
88. Taylor LM, Porter JM 1986 Drug treatment of claudication: Vasodilators, hemorrheologic agents, and antiserotonin drugs. J Vase Surg 3: 374-381
89. The European Study Group 1995 Intravenous pentoxifylline for the treatment of chronic critical limb ischaemia. Eur J Vasc Endovasc Surg 9: 426-436
90. Tonak J, Knecht H, Groitl H 1983 Treatment of circulatory disturbances with pentoxifyllin: a double-blind study with Trental. Pharmatherapeutica 3 (Suppl 1): 126-135
91. Trübestein G 1982 Clinical trials with vasoactive drugs in chronic arterial occlusive disease: Problems and results. In: Couto JR et al (eds) Microcirculation and ischemic vascular diseases. Biomedical Information Corp., New York, pp 399-408
92. Trübestein G, Balzer K, Bisler H et al 1981 Comparative evaluation of the effectiveness of buflomedil, and pentoxifyllin in patients with arterial occlusive disease. Angiology 32: 671-675
93. Trübestein G, Balzer K, Bisler H et al 1984 Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 35: 500-505
94. Trübestein G, Böhme H, Heidrich H et al 1984 Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study. Angiology 35: 701-708
95. Tunis SR, Bass EB, Steinberg EP 1991 The use of angioplasty, bypass surgery and amputation in the management of peripheral vascular disease. N Engl J Med 325: 556-562
96. Ulrich J, Engell HC, Sigaard Andersen J 1973 A plethysmographic study of the spontaneous course of the obliterative disease in the lower leg. Scand J Clin Lab Invest 31 (Suppl 128): 75-81
97. Verheggen R, Schrör K 1993 Effect of naftidrofuryl on platelet-induced vasospasm in vitro. Role of antiserotonergic actions. Drug Res 43: 330-334
98. Waibel P 1992 Unterschied der Prognosen arterieller Rekonstruktionen bei PAVK Stadium II und IV. Ergebnisse der letzten 15 bis 25 Jahre. Vasa J Vase Dis 21: 46-51
99. Waibel P 1994 False aneurysms after reconstruction of peripheral arterial occlusive disease. Vasa J Vasc Dis 23: 43-51
100. Ward A, Clissold SP 1987 Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50-97
101. Waters KJ, Craxford AD, Chamberlain J 1980 The effect of naftidrofuryl (Praxilene) on intermittent claudication. Br J Surg 67: 349-351